Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07654179
NA

Metformin as Adjunct Therapy in Depression-Obesity Comorbidity: Clinical and Genetic Evaluation

Sponsor: Riphah International University

View on ClinicalTrials.gov

Summary

The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1/RPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.

Official title: Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-Obesity Comorbidity and Association With NEGR1/RPL31P12 Variants Based on Genotyping

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2026-06-12

Completion Date

2027-06-11

Last Updated

2026-06-17

Healthy Volunteers

Yes

Interventions

DRUG

Metformin

Tab 500-2000 mg/day (500 mg BD to 1000 mg BD)

DRUG

Antidepressant

Sertraline 50 mg/day + Metformin 500 mg twice daily or Duloxetine 60 mg/day + Metformin 500 mg twice daily or Bupropion XL 150-300 mg/day + Metformin 500 mg twice daily

Locations (1)

Pakistan Railway Hospital

Rawalpindi, Punjab Province, Pakistan